International Stem Cell Corporation (OTCBB:ISCO)
has received the third $1 million tranche of an anticipated private
equity financing of up to $5 million to be funded over the next several
months. The total amount of the financing will allow the Company to move
forward with the construction of its new cGMP cell culture facility and
to continue its therapeutic research, including ongoing pre-clinical
trials. The money will also be allocated to fund equipment, product
development and marketing requirements to increase revenues in the
Company's subsidiary, Lifeline Cell Technology, which makes and sells
specialty cells and growth media.
ISCO is the creator and developer of a new class of stem cells that
remove two of the greatest barriers to the therapeutic use of stem
cells: 1) immune rejection and 2) the ethical issues that surround the
use of embryonic stem cells. ISCO's technology, called
"parthenogenesis," results in the creation of cell lines that may allow
cells from a single donor to be immune-matched to hundreds of millions
of people - thus reducing the dangers of immune rejection. ISCO's
parthenogenetic stem cells come from unfertilized human eggs, thus
avoiding ethical issues associated with embryonic stem cells. To help
promote therapeutic research, ISCO makes its stem cells available to
qualified researchers worldwide.
To subscribe to receive ongoing corporate communications please click on
the following link: http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0.
For more news and information on International Stem Cell Corporation
please visit www.IRGnews.com/coi/ISCO
where you can find the CEO's video, a fact sheet on the company,
investor presentations, and more. ABOUT INTERNATIONAL STEM CELL CORPORATION (ISCO.OB):
International Stem Cell Corporation is a California biotechnology
company focused on developing therapeutic and research products. ISCO's
technology, Parthenogenesis, results in the creation of pluripotent
human stem cell lines from unfertilized human eggs. ISCO scientists have
created the first Parthenogenetic homozygous stem cell line
(phSC-Hhom-4) that can be a source of therapeutic cells that will
minimize immune rejection after transplantation into hundreds of
millions of individuals of differing sexes, ages and racial groups.
These advancements offer the potential to create the first true "Stem
Cell Bank" and address ethical issues by eliminating the need to use or
destroy fertilized embryos. ISCO also produces and markets specialized
cells and growth media worldwide for therapeutic research through its
subsidiary Lifeline Cell Technology. For more information, visit the
ISCO website at: www.internationalstemcell.com.
FORWARD-LOOKING STATEMENTS: Statements pertaining to anticipated future financial and/or
operating results, future growth in research, technology, clinical
development and potential joint venture and other opportunities for the
company and its subsidiary, along with other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by
management constitute forward-looking statements. Any statements that
are not historical fact (including, but not limited to statements that
contain words such as "will," "believes," "plans," "anticipates,"
"expects," "estimates,") should also be considered to be forward-looking
statements. Forward-looking statements involve risks and uncertainties,
including, without limitation, risks inherent in the development and/or
commercialization of potential products, uncertainty in the results of
clinical trials or regulatory approvals, need and ability to obtain
future capital, application of capital resources among competing uses,
and maintenance of intellectual property rights. Actual results may
differ materially from the results anticipated in these forward-looking
statements and as such should be evaluated together with the many
uncertainties that affect the company's business, particularly those
mentioned in the cautionary statements found in the company's Securities
and Exchange Commission filings. The company disclaims any intent or
obligation to update these forward-looking statements.
Key Words: Stem Cells, Biotechnology, Parthenogenesis
International Stem Cell Corporation Kenneth C. Aldrich, Chairman,
CEO 760-940-6383 kaldrich@intlstemcell.com or William
Adams, Chief Financial Officer 760-940-6383 wadams@intlstemcell.com or The
Investor Relations Group 212-825-3210 Investor Relations: Adam
S. Holdsworth aholdsworth@investorrelationsgroup.com or Media
Relations: Laura Colontrelle lcolontrelle@investorrelationsgroup.com |